Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome

作者：Salle V^*; Maziere J C; Brule A; Schmidt J; Smail A; Duhaut P; Maziere C; Makdassi R; Choukroun G; Betsou F; Ducroix J P

来源：European Journal of Internal Medicine, 2012, 23(7): 665-668.

DOI：10.1016/j.ejim.2012.04.006

• Antiphospholipid syndrome
• Systemic lupus erythematosus
• Anti-annexin A2 antibodies

Annexin A2 (ANXA2, an endothelial cell receptor for plasminogen and tissue plasminogen activator) has been identified as a new autoantigen in antiphospholipid syndrome (APS). The aim of the present study was to evaluate the presence of antibodies against the N-terminal domain of annexin A2 (ANXA2) in primary APS (PAPS). By using a synthetic peptide corresponding to the 31 N-terminal amino acids of ANXA2 (ANXA2(N31)) as an antigen, we performed an enzyme-linked immunosorbent assay (ELISA) to measure anti-ANXA2(N31) IgG and IgM anti-bodies in the serum of PAPS patients (n = 19), systemic lupus erythematosus (SLE) patients (n = 50) and healthy blood donors (n = 106). We did not find any statistically differences between the three groups in terms of IgG and IgM anti-ANXA2(N31) titres. Elevated IgG anti-ANXA2(N31) titres were not observed in the serum of PAPS or SLE patients who had previously tested positive for anti-ANXA2 antibodies. Thus, the ANXA2 N-terminal domain does not appear to be the target antigen for anti-ANXA2 antibodies in APS.

• 出版日期2012-10